(PR-inside.com) Biothera has expanded the second arm of its clinical trial evaluating whether the combination of Imprime PGG and Erbitux can achieve positive outcomes for metastatic colorectal cancer (mCRC) patients without the use of chemotherapy, the company announced today. Imprime PGG is a targeted immunotherapeutic drug candidate from Biothera that works synergistically with monoclonal antibodies through specific innate immune cell activation. Erbitux (cetuximab) is an anti-tumor monoclonal antibody from ImClone Systems that is approved for the treatment of colon cancer and head-and-neck cancer. 'We are excited about the initial results of the second arm of the trial,' ..
More...
More...